

February 12, 2018

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra -Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Sub: Launch of XIGDUO[®] XR

We refer to our earlier communication dated October 17, 2017 and December 14, 2017, wherein we had informed that the FDC of Dapagliflozin + Metformin Hydrochloride film coated tablets (XIGDUO[®] XR) was expected to be launched in India in Q4 of FY 2017-18.

With regard to the same, we wish to update that the Company has initiated the commercial launch of XIGDUO[®] XR.

XIGDUO[®] XR is a product of AstraZeneca Group and has been approved in 61 countries to date including US, EU and Japan.

XIGDUO[®] XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.

Kindly take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited



Pratap Rudra

Company Secretary & Legal Counsel

